A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
NCT04016077
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Healthy Participants
Interventions
DRUG:
PF-06651600 30 mg
Sponsor
Pfizer